15.09.2023 • NewsAzelisChemical DistributionPeople

Azelis Appoints Evy Hellinckx as New CEO for EMEA

Specialty chemicals and food ingredients distributor Azelis has appointed Evy Hellinckx as CEO of Azelis EMEA, effective Jan. 1, 2024. She succeeds Anna Bertona, who will take on her new role as Azelis Group CEO at the beginning of next year.

Hellinckx has held strategic leadership roles within Azelis since 2016. Currently, she is managing director of Azelis Benelux. Prior to this role, Hellinckx was strategy and business development director for EMEA.

Before joining Azelis, Hellinckx spent two years in the medical devices division of Johnson & Johnson, and ten years in strategic consulting at Bain. She holds a master’s degree in Commercial Engineering from the Catholic University of Leuven in Belgium.

Hans Joachim Müller, the outgoing Azelis Group CEO, commented: “I am thrilled to welcome Evy as she steps into her new role as CEO of EMEA. Both Anna Bertona, who will succeed me as Group CEO, and I have had the pleasure of working closely with Evy over the years. We are confident that her intimate familiarity with our principal base and customer needs in EMEA on one hand, and the value Azelis can bring to both on the other will allow her to continue growing the Group’s footprint in the region. We are excited to see the dynamism and perspectives she will bring to her new role.”

Source: Azelis
Source: Azelis

Free Virtual Event

Digital Validation
Transforming from Paper to Digital

Digital Validation

Our experts will delve into the recently released International Society for Pharmaceutical Engineering (ISPE) Good Practice Guide: Digital Validation

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.